# Ipamorelin

> Ipamorelin is a selective growth hormone releasing peptide developed to stimulate GH secretion while largely avoiding the cortisol, prolactin, and appetite effects seen with earlier GHRPs. It has been studied in clinical trials, including for gastrointestinal motility applications, and is widely used in research and community protocols due to its comparatively clean side-effect profile. Its GH-releasing magnitude per dose is generally reported as more modest than GHRP-2, GHRP-6, or hexarelin, but its tolerability has made it a common choice for extended use. It is frequently combined with a GHRH analog to amplify the GH pulse.

- URL: https://www.lifeconverted.com/peptides/ipamorelin
- Also known as: NNC 26-0161
- Primary category: Growth Hormone Peptides
- Effectiveness rank: #14 in Muscle & Performance; #2 in Growth Hormone Peptides
- Evidence level: Moderate evidence
- Route: Subcutaneous (Injected subcutaneously, commonly before bed or post-workout)
- Dose range: 100-300 mcg
- Dose tiers: low 100 mcg; moderate 200 mcg; high 300 mcg
- Half-life: ~2 hours
- Timing: ~30 min before bed, empty stomach
- Cycle: 8-12 weeks on, 4 weeks off (Reported desensitization is minimal compared to other GHRPs, though cycling remains common practice)
- Storage: Store lyophilized powder refrigerated (2-8°C), protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within 2-4 weeks.

## Mechanism of action

Ipamorelin selectively activates the growth hormone secretagogue receptor (GHS-R1a) to stimulate pulsatile GH release from the pituitary. Unlike earlier GHRPs, it shows minimal activity on pathways linked to cortisol, prolactin, or the hunger-driving effects of ghrelin signaling, which researchers attribute to its more selective receptor binding profile.

## Reported benefits

- Selective GH release with minimal off-target effects
- Improved sleep quality
- Supports recovery and lean mass
- Generally well tolerated for extended use

## Reported side effects

- Mild headache
- Injection-site redness
- Mild water retention
- Rare dizziness

## Common protocols

- Ipamorelin + CJC-1295 DAC
- Ipamorelin + CJC-1295 (no DAC)

## Stacking notes

Most commonly stacked with CJC-1295 (with or without DAC); favored in stacks where cortisol, prolactin, or appetite side effects are undesirable.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer